Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

Inclusion Criteria:

Patient is 18 years of age or older
Patient (or patient's legally authorized representative) is willing and able to provide written informed consent
Patient is willing and able to comply with the protocol, including follow-up visits
Documented paroxysmal or persistent atrial fibrillation or strong suspicion of atrial fibrillation (i.e, palpitations)
Patient is indicated for the Reveal XT insertable cardiac monitor or other commercially-available and substantially equivalent Medtronic insertable cardiac monitor
Recent HF event within prior 120 days (HF event defined as meeting any one of the following two criteria: 1. Admission with primary diagnosis of HF 2. Intravenous HF therapy (e.g. IV diuretics/vasodilators) or ultrafiltration at any one of the following settings: admission with secondary/tertiary diagnosis of HF, emergency department, ambulance, observation unit, urgent care, HF/cardiology clinic, patient's home
Willing and able to transmit data via CareLink

Exclusion Criteria:

Patient is pregnant
Patient has been participating in another study that may interfere with the IDENTIFY-HF protocol required procedures
Endstage (Stage D or New York Heart Association class IV) heart failure
Asymptomatic (Stage B or New York Heart Association class I) heart failure
Severe aortic stenosis or insufficiency
Existing insertable cardiac monitor implanted for more than 1 year
Existing implantable pulse generator, implantable cardioverter defibrillator, cardiac resynchronization therapy device
Severe renal impairment (estimated glomerular filtration rate <25mL/min)
Myocardial infarction within prior 30 days